C J Currie
Overview
Explore the profile of C J Currie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sabah S, Moon J, Jenkins-Jones S, Morgan C, Currie C, Wilkinson J, et al.
Bone Joint J
. 2018 Jan;
100-B(1):20-27.
PMID: 29305446
Aims: The aim of this study was to determine whether patients with metal-on-metal (MoM) arthroplasties of the hip have an increased risk of cardiac failure compared with those with alternative...
2.
Holden S, Jenkins-Jones S, Morgan C, Peters J, Schernthaner G, Currie C
Diabet Med
. 2017 Feb;
34(6):770-780.
PMID: 28173634
Aims: To characterize the prevalence of Type 2 diabetes between 1991 and 2013 in the UK and to determine whether corresponding glucose control and survival had changed in the diabetic...
3.
Stoekenbroek R, Rensing K, Bernelot Moens S, Nieuwdorp M, DeVries J, Zwinderman A, et al.
Atherosclerosis
. 2015 Apr;
240(2):318-23.
PMID: 25864162
Aims: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk....
4.
Holden S, Jenkins-Jones S, Morgan C, Schernthaner G, Currie C
Diabetes Obes Metab
. 2014 Nov;
17(4):350-62.
PMID: 25399739
Aims: To evaluate the association between insulin exposure and all-cause mortality, incident major adverse cardiovascular events (MACE) and incident cancer in people with type 2 diabetes treated with insulin monotherapy....
5.
Bannister C, Holden S, Jenkins-Jones S, Morgan C, Halcox J, Schernthaner G, et al.
Diabetes Obes Metab
. 2014 Jul;
16(11):1165-73.
PMID: 25041462
Aims: Clinical and observational studies have shown an increased risk of cardiovascular events and death associated with sulphonylureas versus metformin. However, it has never been determined whether this was due...
6.
Currie C, Holden S
Diabetes Obes Metab
. 2014 Jul;
16(10):881-4.
PMID: 25040702
No abstract available.
7.
Morgan C, Mukherjee J, Jenkins-Jones S, Holden S, Currie C
Diabetes Obes Metab
. 2014 Apr;
16(10):977-83.
PMID: 24762119
Aims: To compare the risk of major adverse cardiovascular events (MACE) and mortality for combination therapies with metformin and either sulphonylurea (SU) or dipeptidyl peptidase-4 inhibitor (DPP-4i). Methods: Data were...
8.
Morgan C, Mukherjee J, Jenkins-Jones S, Holden S, Currie C
Diabetes Obes Metab
. 2014 Apr;
16(10):957-62.
PMID: 24720708
Aims: To evaluate the risk of all-cause mortality and major adverse cardiovascular events (MACE) for patients exposed to first-line monotherapy with sulphonylurea or metformin. Methods: Data were from the Clinical...
9.
Holden S, Currie C
Diabetes Obes Metab
. 2014 Feb;
16(10):885-90.
PMID: 24533964
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of...
10.
Holden S, Gale E, Jenkins-Jones S, Currie C
Diabetes Obes Metab
. 2014 Jan;
16(6):553-9.
PMID: 24410846
Aims: We set out to estimate the prevalence rate of insulin use in the UK population, the total number of people in the UK who use insulin, the proportion of...